WO1994015967B1 - Agents for the prevention and treatment of parkinson's disease - Google Patents
Agents for the prevention and treatment of parkinson's diseaseInfo
- Publication number
- WO1994015967B1 WO1994015967B1 PCT/EP1993/003722 EP9303722W WO9415967B1 WO 1994015967 B1 WO1994015967 B1 WO 1994015967B1 EP 9303722 W EP9303722 W EP 9303722W WO 9415967 B1 WO9415967 B1 WO 9415967B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- parkinson
- inhibitor
- reagent
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
Agents and methods for the diagnosis and therapy of Parkinson's disease and related conditions are disclosed. Such agents include antisense molecules of one gene implicated in Parkinson's disease, as well as analogues and derivatives of this molecule, and protein molecules expressed by this gene.
Claims
AMENDED CLAIMS
[received by the Internationa! Bureau on 2 August 1994 (02.08.94); original claims 1 1-20 replaced by amended claims 11-18; remaining claims unchanged (1 page)]
11. The reagent of claim 8, wherein said reagent comprises a nucleic acid sequence that is complementary to the nucleotide sequence of SEQ ID NO:1.
12. The reagent of claim 7, wherein said reagent is a protein.
14. An antibody or fragment of an antibody to the protein in claim 12, which is capable of binding to a Cadrac gene product.
15. A method of treating Parkinson's disease which comprises providing to an individual, in need of such treatment, an effective amount of an inhibitor of
Cadrac.
16. The method of claim 15, wherein said inhibitor is a protein. 17. The method of claim 16, wherein said inhibitor is an antibody, or fragment thereof.
18. The method of claim 15, wherein said inhibitor is a nucleic acid molecule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU69552/94A AU6955294A (en) | 1992-12-31 | 1993-12-30 | Agents for the prevention and treatment of parkinson's disease |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2086576 CA2086576A1 (en) | 1992-12-31 | 1992-12-31 | Potential target for an immunotherapeutic approach to stop parkinson's disease in humans: cdna and protein structure for a putative activator of human dopamine receptor and human brain ca2+ channel protein reconstructed from the antisense strand of the human app gene |
| CA2,086,576 | 1992-12-31 | ||
| US13216993A | 1993-10-06 | 1993-10-06 | |
| US08/132,169 | 1993-10-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994015967A1 WO1994015967A1 (en) | 1994-07-21 |
| WO1994015967B1 true WO1994015967B1 (en) | 1994-09-01 |
Family
ID=25675788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1993/003722 Ceased WO1994015967A1 (en) | 1992-12-31 | 1993-12-30 | Agents for the prevention and treatment of parkinson's disease |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU6955294A (en) |
| WO (1) | WO1994015967A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1538163A3 (en) * | 2000-11-01 | 2005-06-15 | Insight Biotechnology Limited | Phosphorylated Amyloid-Beta 1-43 Protein and its use in the treatment of Alzheimer's disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005138A1 (en) * | 1988-11-08 | 1990-05-17 | The Children's Medical Center Corporation | Cytotoxic amyloid precursors and screening assays using them |
-
1993
- 1993-12-30 WO PCT/EP1993/003722 patent/WO1994015967A1/en not_active Ceased
- 1993-12-30 AU AU69552/94A patent/AU6955294A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2174315A1 (en) | Oligonucleotide modulation of multidrug resistance-associated protein | |
| JP2004507263A (en) | Antisense oligonucleotides to VR1 | |
| AU1664695A (en) | Process for producing endotoxin-free or endotoxin-poor nucleic acids and/or oligonucleotides for gene therapy | |
| BR9206049A (en) | Compound, processes for preparing the compound, for sequence specific recognition of a double-stranded polynucleotide, to modulate the expression of a gene in an organism, to treat conditions associated with unwanted protein production in an organism, to induce degradation of DNA or RNA in cells of an organism and to exterminate cells or viruses and pharmaceutical composition | |
| EP1361229A3 (en) | Use of Tyrosine Kinase (PYK2) to produce antibodies | |
| WO1995021919A3 (en) | Protein having tpo activity | |
| CA2342770A1 (en) | Ly6h gene | |
| WO2003035679A3 (en) | Molecules | |
| EP0641215A4 (en) | Protease-resistant thrombomodulin analogs. | |
| Dalbies et al. | Linkage isomerization reaction of intrastrand cross-links in trans-diamminedichloroplatinum (II)-modified single-stranded oligonucleotides | |
| AU5596998A (en) | Pyk2 related products and methods | |
| WO1998006841A3 (en) | Two human nsp-like proteins | |
| WO1997023611A3 (en) | Nucleic acid sequences of genes of the high mobility group proteins and uses thereof | |
| ATE465261T1 (en) | INTEGRIN-COUPLED KINASE, THEIR INHIBITORS AND THEIR USE FOR THERAPEUTIC TREATMENT METHODS; GENE THERAPY AND PROVISION OF INHIBITORS THAT ACTION AS PSEUDOSUBSTRATES | |
| WO1998011234A3 (en) | Human protein kinases | |
| EP1279744A3 (en) | Identification and use of molecules implicated in pain | |
| EP1284297A3 (en) | Identification and use of molecules implicated in pain | |
| WO1999025829A3 (en) | Cdk2 protein and cdk2 protein complexes | |
| Safer et al. | DNA affinity labeling of adenovirus type 2 upstream promoter sequence-binding factors identifies two distinct proteins | |
| Verspieren et al. | Effect of RNA secondary structure and modified bases on the inhibition of trypanosomatid protein synthesis in cellfree extracts by antisense oligodeoxynucleotides | |
| WO1994015967B1 (en) | Agents for the prevention and treatment of parkinson's disease | |
| WO1998025956A3 (en) | Human GTP-binding proteins | |
| Ho et al. | Esterification of terminal phosphate groups in nucleic acids with sorbitol and its application to the isolation of terminal polynucleotide fragments | |
| Nashimoto | 3'truncated tRNAArg is essential for in vitro specific cleavage of partially synthesized mouse 18S rRNA | |
| WO1999054436A3 (en) | Nucleic acids and proteins of c. elegans insulin-like genes and uses thereof |